Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Other Non-Commercial Sponsor
University of Pennsylvania
Patients eligible to participate in this trial will receive either rAd-IFN on the first day of the trial plus celecoxib on Days 1-14 and gemcitabine on days 14 -21 of the treatment cycle, or celecoxib and gemcitabine as described above. Gemcitabine will be received every 3 weeks until the end of the trial.